期刊文献+
共找到14篇文章
< 1 >
每页显示 20 50 100
Etravirine片剂获得FDA的优先审批
1
作者 姚瑜 《国外医药(抗生素分册)》 CAS 2008年第2期91-91,共1页
非核苷逆转录酶抑制剂(NNRTI)etravirine片剂(商品名:Intelence)经过优先审批程序已于2008—01—18获得FDA批准,与其他的抗逆转录病毒药物联用治疗经其他抗逆转录病毒药物治疗失败的成年HIV感染者。Etrabirine的作用机制是阻断HI... 非核苷逆转录酶抑制剂(NNRTI)etravirine片剂(商品名:Intelence)经过优先审批程序已于2008—01—18获得FDA批准,与其他的抗逆转录病毒药物联用治疗经其他抗逆转录病毒药物治疗失败的成年HIV感染者。Etrabirine的作用机制是阻断HIV复制过程所需要的一种酶。之所以开发etravirine,是由于发现其对突变的具有NNRTI抗性的HIV毒株表现出体外活性之故。 展开更多
关键词 etravirine FDA批准 审批程序 非核苷逆转录酶抑制剂 片剂 抗逆转录病毒药物 etravirine HIV感染者
暂未订购
Raltegravir,EtraVirine和Darunavir 3药联用可显著抑制HIV患者的病毒载量
2
《国外医药(抗生素分册)》 CAS 2008年第5期239-240,共2页
一项在法国进行的名为TRIO的临床研究结果(于2008—08-07召开的第17届国际艾滋病会议上发表)显示,如果将3种新近批准的HIV药物联合使用,同时结合优化的背景疗法,对患者的病毒载量有明显的抑制作用。
关键词 etravirine 病毒载量 HIV患者 HIV药物 临床研究 TRIO 联合使用 抑制作用
暂未订购
FDA批准首个非核苷类逆转录酶抑制剂etravirine
3
《世界临床药物》 CAS 2008年第2期67-67,共1页
FDA最近快速批准了Tibotec Pharmaceuticals公司的抗HIV药物—首个非核苷类逆转录酶抑制剂etravirin片剂(Intelence)。本品对于那些对常规非核苷类逆转录酶抑制剂和其他抗逆转录病毒药物抵抗的HIV成年患者具有抗病毒活性。
关键词 非核苷类逆转录酶抑制剂 etravirine FDA批准 Pharmaceuticals公司 抗HIV药物 抗逆转录病毒 抗病毒活性 成年患者
暂未订购
A Novel Validated Stability Indicative UP-LC Method for Etravirine for the Determination of Process Related and Degradation Impurities
4
作者 Mohanareddy Chilukuri Katreddi H. Reddy +1 位作者 Papadasu Narayanareddy Madireddi Venkataramana 《American Journal of Analytical Chemistry》 2012年第12期840-848,共9页
A novel stability indicating reverse phase ultra performance liquid chromatographic (UP-LC) method has been developed for Etravirine along with eight impurities (imp-1, imp-2, imp-3, imp-4, imp-5, imp-6, imp-7 and imp... A novel stability indicating reverse phase ultra performance liquid chromatographic (UP-LC) method has been developed for Etravirine along with eight impurities (imp-1, imp-2, imp-3, imp-4, imp-5, imp-6, imp-7 and imp-8) and validated as per ICH recommendations. Stress degradation conditions were established for Etravirine by subjecting it to stress conditions of acid, base, oxidation, humidity, thermal and photolysis. Significant degradation is observed in base stress condition and the major degradant (RRT at about 0.94) is identified by LC-MS and spectral analysis. The stress samples were assayed against a qualified reference standard and the mass balance was found close to 99.0%. Efficient chromatographic separation was achieved on a Shimpack ODS-II stationary phase with a gradient mobile phase combination. Quantification was carried at 303 nm at a flow rate of 0.6 mL?min–1. The resolution between Etravirine and eight potential impurities is found to be greater than 2.0. Regression analysis shows as r value (correlation coefficient) of greater than 0.999 for Etravirine and eight potential impurities. This method is capable to detect the impurities of Etravirine at a level of 0.003% with respect to test concentration of 1.0 mg·mL–1. 展开更多
关键词 etravirine Forced DEGRADATION Ultra-Performance Validation STABILITY-INDICATING
暂未订购
Spectrophotometric Determination of Etravirine in Bulk and Pharmaceutical Formulations
5
作者 D. Murali S. V. Venkatrao C. Rambabu 《American Journal of Analytical Chemistry》 2014年第2期77-82,共6页
Two simple, rapid, sensitive, accurate, precise and economical Visible Spectrophotometric methods have been developed for the determination of Etravirine in pure and pharmaceutical formulations. These methods (A and B... Two simple, rapid, sensitive, accurate, precise and economical Visible Spectrophotometric methods have been developed for the determination of Etravirine in pure and pharmaceutical formulations. These methods (A and B) were based on nucleophilic substitution and oxidative coupling reactions of Etravirine by 1,2-naphtha quinone-4-sulphonate (NQS) in alkaline medium and 3-methyl-2-benzothiazolinone hydrazone (MBTH) in acidic medium with the maximum absorbance at 414 nm and 635 nm respectively. Linearity was obtained in the concentration range of 5 -30 μg/ml and 2 -10 μg/ml which was corroborated by the correlation coefficient (r) values of 0.9995 and 0.9996 respectively. The methods developed were validated with respect to linearity, accuracy (recovery), precision, Sandell’s sensitivity, molar extinction coefficient and specificity. The proposed methods are successfully applied for the determination of Etravirine in bulk and pharmaceutical formulations and results were validated statistically by recovery studies. 展开更多
关键词 etravirine 1 2-Napthaquinone 4-Sulphonate 3-Methyl-2-Benzothiazolinone Hydrazone
在线阅读 下载PDF
非核苷类逆转录酶抑制剂Etravirine
6
《药学进展》 CAS 2007年第6期282-283,共2页
Etravirlne(曾用代号:R-165335,TMC-125)的化学名为:“晦基-5-溴-2-(4-氰酚胺)嘧啶4氧]-3,5-二甲基苄腈。化学结构式如下:
关键词 非核苷类逆转录酶抑制剂 etravirine HIV
暂未订购
Etravirine有希望治疗HIV感染
7
作者 蒋晓丽 《国外药讯》 2004年第3期24-24,共1页
关键词 etravirine HIV感染 逆转录病毒 Tibotec公司 制药工业
在线阅读 下载PDF
Optimized Antiretroviral Therapy with Darunavir/Ritonavir, Etravirine and/or Raltegarvir: A Salvage Therapy Option in HIV-1 Infected Patients with Long-Term Therapeutic Failures, about 23 Cases
8
作者 Vincent Guiyedi Olivier Mounoury +7 位作者 Soraya Boucherit Pascale Longuet CBrunet-Francois Eric Kendjo JLEcobichon Madeleine Okome-Nkoumou Catherine Leport FRaffi 《World Journal of AIDS》 2012年第4期300-305,共6页
Objectives: The aims of this study was to analyze the immuno-virologic response after optimised background antiretroviral therapy (OBT) associated to new active antiretroviral treatment (ART) in HIV-1 infected patient... Objectives: The aims of this study was to analyze the immuno-virologic response after optimised background antiretroviral therapy (OBT) associated to new active antiretroviral treatment (ART) in HIV-1 infected patients with chronic virologic failure. Methods: We conducted a descriptive analysis of the immuno-virologic responses in HIV-1 adult infected patients: 1) harbouring multiple therapeutic failures with ART;2) with no virologic response obtained over 10 years (1997-2008);and 3) treated with OBT combined with new drugs including at least 1 of the 3 active ART among darunavir/ritonavir, etravirine and raltegravir;4) observed between month 0 (M0), before new ART to month 12 (M12) after new ART initialisation. Results: Twenty three patients were included in the study. After OBT, the proportion of patients with undetectable viral load was significantly higher at M6 and M12 than M0 (86% and 73% versus 0%, p = 0.03, respectively). At the same period, the median HIV viral load decreased significantly in 19/23 (83%) patients from 4.3 to 1.69log10 HIV-1 RNA copies/ml (p 3 [0 - 604] to 449/mm3 [130 - 964] between M0 and M12 (p 3 decreased from 57% to 23% (p = 0.02). Tolerability was good and no death was recorded during the 12-month' follow-up. Conclusions: These results show that the combination of OBT with the new ART can offer a salvage therapy in patients presenting a long-term history of virologic failures. 展开更多
关键词 Darunavir/Ritonavir etravirine RALTEGRAVIR HIV-1
暂未订购
美国FDA关于抗HIV药物的临床前药效学评价标准
9
作者 陈欢 王睿睿 郑永唐 《中国药理学通报》 CAS CSCD 北大核心 2012年第10期1352-1355,共4页
药物治疗是目前唯一有效治疗艾滋病的手段,而我国至今尚无自主知识产权的抗HIV药物上市,药物研发的任务紧迫且艰巨。药物的临床前药效学评价对后续的临床实验具有重要的指导意义。该文以Etravirine为例,介绍和讨论FDA抗HIV药物的临床前... 药物治疗是目前唯一有效治疗艾滋病的手段,而我国至今尚无自主知识产权的抗HIV药物上市,药物研发的任务紧迫且艰巨。药物的临床前药效学评价对后续的临床实验具有重要的指导意义。该文以Etravirine为例,介绍和讨论FDA抗HIV药物的临床前药效学评价指导原则,分析了抗HIV药物临床前药效学研究部分的实验要点和重点,希望为完善符合我国国情的抗HIV药物临床前研究标准提出参考。 展开更多
关键词 FDA 指导原则 抗HIV药物 临床前 药效学 etravirine
暂未订购
二芳基嘧啶类HIV-1非核苷类逆转录酶抑制剂研究进展
10
作者 田兴涛 谢蓝 《药学学报》 CAS CSCD 北大核心 2010年第2期177-183,共7页
2008年FDA批准上市的新一代非核苷类逆转录酶抑制剂Etravirine(TMC125)和Ⅲ期临床候选药Rilpivirine(TMC278)都是二芳基嘧啶(DAPY)类化合物,均对HIV野生型和多种耐药性病毒株有相当强的抑制作用。DAPY类药物的发现和发展是多学科合作研... 2008年FDA批准上市的新一代非核苷类逆转录酶抑制剂Etravirine(TMC125)和Ⅲ期临床候选药Rilpivirine(TMC278)都是二芳基嘧啶(DAPY)类化合物,均对HIV野生型和多种耐药性病毒株有相当强的抑制作用。DAPY类药物的发现和发展是多学科合作研发新药的成功范例。本文综述了新一代HIV非核苷类逆转录酶抑制剂DAPY类化合物的发现、发展及最新研究进展。 展开更多
关键词 人类免疫缺陷病毒 非核苷类逆转录酶抑制剂 二芳基嘧啶类化合物 etravirine Rilpivirine
原文传递
Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase
11
作者 Emilio Gallicchio 《Computational Molecular Bioscience》 2012年第1期7-22,共16页
The results of computer simulations of the binding of etravirine (TMC125) and rilpivirine (TMC278) to HIV reverse transcriptase are reported. It is confirmed that consistent binding free energy estimates are obtained ... The results of computer simulations of the binding of etravirine (TMC125) and rilpivirine (TMC278) to HIV reverse transcriptase are reported. It is confirmed that consistent binding free energy estimates are obtained with or without the application of torsional restraints when the free energies of imposing the restraints are taken into account. The restraints have a smaller influence on the thermodynamics and apparent kinetics of binding of TMC125 compared to the more flexible TMC278 inhibitor. The concept of the reorganization free energy of binding is useful to understand and categorize these effects. Contrary to expectations, the use of conformational restraints did not consistently enhance convergence of binding free energy estimates due to suppression of binding/unbinding pathways and due to the influence of rotational degrees of freedom not directly controlled by the restraints. Physical insights concerning the thermodynamic driving forces for binding and the role of “jiggling” and “wiggling” motion of the ligands are discussed. Based on these insights we conclude that an ideal inhibitor, if chemically realizable, would possess the electrostatic charge distribution of TMC125, so as to form strong interactions with the receptor, and the larger and more flexible substituents of TMC278, so as to minimize reorganization free energy penalties and the effects of resistance mutations, suitably modified, as in TMC125, so as to disfavor the formation of non-binding competent extended conformations when free in solution. 展开更多
关键词 HIV-RT TMC125 TMC278 etravirine Rilpivirine BINDING Free Energy
暂未订购
有关公司公布3种新型抗HIV药物的疗效
12
《药学进展》 CAS 2008年第9期430-431,共2页
关键词 RALTEGRAVIR etravirine Vicriviroc 整合酶抑制剂 非核苷逆转录酶抑制剂 CCR5抑制剂
暂未订购
抗感染药
13
《国外药讯》 2008年第1期25-28,共4页
Raltegravir给HIV感染者带来新希望;Prezista HIV用药方案的研究数据;Etravirine复方在面对HIV-1耐药方面取得成功;Basilea公司的新抗生素Ⅲ期试验数据有效;富山化学公司的garenoxacin在首个市场上市;
关键词 抗感染药 etravirine HIV感染者 Ⅲ期试验数据 用药方案 HIV-1 抗生素
暂未订购
治疗耐药性人类免疫缺陷病毒感染的新方法
14
作者 陶梅梅 《英国医学杂志中文版》 2007年第5期286-286,共1页
耐药性对很多人类免疫缺陷病毒(HIV)患者是一个大问题。幸运的是,有两种专门针对耐药性HIV感染的药物即将上市。在最近的随机对照研究中,地瑞纳韦(darunavir,一种蛋白酶抑制剂)和etravirine(一种非核苷类逆转录酶抑制剂)均取... 耐药性对很多人类免疫缺陷病毒(HIV)患者是一个大问题。幸运的是,有两种专门针对耐药性HIV感染的药物即将上市。在最近的随机对照研究中,地瑞纳韦(darunavir,一种蛋白酶抑制剂)和etravirine(一种非核苷类逆转录酶抑制剂)均取得了良好的疗效,与对照组相比,它们均能更好地抑制病毒复制,且未见明显不良反应,但是。在etravirine治疗组中已经发现耐药的病毒株。 展开更多
关键词 人类免疫缺陷病毒感染 耐药性HIV感染 治疗组 etravirine 非核苷类逆转录酶抑制剂 随机对照研究 蛋白酶抑制剂 抑制病毒复制
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部